Splice switching of membrane-bound FLT1 into a soluble protein as a treatment for pathological angiogenesis
This study demonstrates that splice-switching oligonucleotides can therapeutically redirect FLT1 pre-mRNA processing to increase the production of soluble FLT1, a natural VEGF inhibitor, thereby attenuating pathological angiogenesis without altering total FLT1 gene expression.
Original paper licensed under CC BY 4.0 (https://creativecommons.org/licenses/by/4.0/). This is an AI-generated explanation of a preprint that has not been peer-reviewed. It is not medical advice. Do not make health decisions based on this content. Read full disclaimer
The human eye relies on a delicate network of blood vessels to deliver oxygen and nutrients to the retina, the light-sensitive tissue at the back of the eye. When this system malfunctions, new vessels can grow in a chaotic, leaky manner, leading to vision loss in conditions like age-related macular degeneration. For decades, doctors have treated these diseases by injecting drugs that block a specific growth signal called VEGF, which acts as a chemical instruction telling blood vessels to multiply. While effective, this approach requires repeated injections because the drugs are external agents that the body eventually clears away. Nature, however, has its own way of controlling this process. Inside our cells, there is a built-in mechanism that can produce a natural version of this drug, a decoy that soaks up the growth signal before it can cause damage. This natural decoy is a protein called soluble FLT1, which is created by a cell's internal machinery when it reads a specific gene. The challenge for scientists has been figuring out how to coax the body's own cells to make more of this natural protector without disrupting other essential functions.
A team of researchers at the Centre for Eye Research Australia and the University of Melbourne has taken a significant step toward solving this problem. They focused on the gene responsible for making the FLT1 protein, which can be processed in two different ways. One version stays stuck to the cell membrane and acts as a receptor, while the other version is cut loose to become the soluble decoy that fights disease. The researchers wanted to see if they could use tiny, custom-made strands of genetic material, known as splice-switching oligonucleotides, to nudge the cell's machinery toward producing the soluble, protective version. These strands work like a physical barrier, blocking specific spots on the genetic blueprint to force the cell to choose a different path when assembling the final protein. By testing dozens of these strands in human cells, the team identified specific locations on the gene where blocking the process successfully increased the amount of the soluble decoy protein.
The study began by screening a large panel of these genetic strands in a laboratory cell line to see which ones could shift the balance toward the protective protein. The researchers found that strands targeting a specific region near the beginning of a long section of the gene, known as intron 13, were particularly effective. When these strands blocked the usual path, the cell produced significantly more of the soluble decoy protein, yet the total amount of genetic instructions for the gene remained unchanged. This confirmed that the treatment was not simply turning the gene on louder, but was instead changing how the instructions were being read and assembled. The team also discovered that strands targeting a different, more distant part of the same gene section could achieve a similar result, suggesting there are multiple ways to influence this process.
To ensure these findings would matter for actual human eyes, the researchers moved beyond simple lab cells to a more realistic model. They identified that a specific type of support cell in the retina, called Müller glia, naturally contains the gene in question and plays a central role in eye health. However, these cells do not naturally produce enough of the gene's instructions to test the new treatments effectively. To overcome this, the team used a precise genetic tool to boost the natural production of the gene in these retinal cells by nearly 740 times. This created a robust model that mimicked the conditions needed to see if the treatments would work in a real eye environment. When they applied the most promising genetic strands to these enhanced retinal cells, the results were clear: the cells produced large amounts of the soluble decoy protein. Crucially, when the researchers tested the fluid surrounding these treated cells, they found that the new protein successfully blocked the growth signal that causes dangerous blood vessel formation.
The study highlights two specific genetic strands, which the researchers labeled SSO-16 and SSO-19, as the most effective candidates. These strands did not just increase the amount of the protective protein; they also significantly reduced the activity of the harmful growth signal in the test system. Interestingly, the way these two strands worked differed from the others. While some strands worked by blocking the initial cut-and-paste step of gene assembly, these two appeared to influence a later step involving how the genetic message is finalized and released. This distinction is important because it suggests that the body's control over this gene is more complex than previously thought, involving multiple checkpoints that can be targeted. The researchers noted that while their results in the lab were strong, the path to treating patients involves further steps, including testing in living animals and ensuring the strands can reach the right cells in the eye.
This work provides a new blueprint for treating blinding diseases by turning the body's own defense mechanisms into a therapy. Instead of relying solely on external drugs, the approach aims to reprogram the cells within the eye to produce their own natural shield against abnormal blood vessel growth. The identification of these specific regulatory regions offers a clear target for future drug development. If successful, this method could lead to treatments that are more durable and perhaps require fewer interventions than current therapies, offering hope for millions of people facing vision loss. The study confirms that it is possible to precisely alter how a gene is processed to favor a protective outcome, opening a new avenue for managing the complex biology of eye disease.
Drowning in papers in your field?
Get daily digests of the most novel papers matching your research keywords — with technical summaries, in your language.